Therapies with novel antiplatelet agents and anticoagulants are the fo
cus of current research. When used separately or in combination, these
agents prevent generation of thrombin by activated platelets. The new
therapies, in conjunction with judicious use of fibrinolytic drugs an
d mechanical interventions, are revolutionizing the management of pati
ents with acute coronary syndromes.